Efficacy and safety of bulevirtide monotherapy given at 2 mg or 10 mg dose level once daily for treatment of chronic hepatitis delta: week 48 primary end point results from a phase 3 randomized, multicenter, parallel design study

Heiner Wedemeyer, Soo Aleman, Maurizia Rossana Brunetto, Antje Blank, Pietro Andreoné, Pavel Bogomolov, Vladimir Chulanov, Nina Mamonova, Natalia Geyvandova, Morozov Viacheslav, Olga Sagalova, Tatyana Stepanova, Dmitry Manuilov, Vithika Suri, Qi An, John F. Flaherty, Anu Osinusi, Julian Schulze zur Wiesch, Markus Cornberg, Stefan Zeuzem, Pietro Lampertico